Cheil Pharma Holdings and Jeil Pharm held the 61st and 4th regular shareholders’ meetings in sequence at 9 am on the 23rd in the auditorium at the headquarters and decided to pay 14% cash dividends.
On the day, Seong Suk-je, president of Jeil Pharmaceutical said, “With the unprecedented new virus called Corona 19, daily life is changing all over the world, and accordingly, the economic downturn continues for a long time.” We are facing various challenges for the whole,” he said.
President Sung said, “It is aggravated by difficulties that are difficult to handle, but thanks to the unchanging support of shareholders and the dedication of all employees last year, we were able to achieve a growth rate of 3% compared to the previous year.” I will go.”
Last year, Onconic Therapeutics’ dual-target anticancer drug JPI-547 and reflux esophagitis drug JP-1366 were prepared for global clinical trials last year, and JPI-289 stroke treatment, a representative new drug, was conducted in phase 2A cohort 3, diabetes treatment. It was reported that the R&D of Jeil Pharm, including the European phase 1 clinical trial of JP-2266, proceeded smoothly as planned.
Han Sang-cheol, president of Cheil Pharma Holdings, said, “As the leading holding company, we want to prepare for the future by laying the foundation for a 100-year company.” did.
President Han said, “Last year, we made large-scale facility investments for the remodeling of the patch production facility and the introduction of new facilities. In the second half of this year, the completion of a new factory and full-scale production of products will raise the status of the famous patch maker to the next level in the domestic and export markets. “He said.
In addition, “Cheil Pharm will provide support for securing new drug development investment and smooth global clinical advancement through Onconic Therapeutics, a new drug R&D company.” “We will further accelerate the approval and release of innovative new drugs.”
Meanwhile, Kibong Park, former head of the Yangjaenam Financial Center of KB Kookmin Bank and former head of the Gangnam 1 Regional Headquarters of KB Kookmin Bank, was appointed as the outside director and outside director of Cheil Pharma Holdings as the original draft of the stockholders’ agenda. Lotte Insurance Corporate Sales Headquarters and current STM-NET Sales Executive Vice President were appointed.